Joseph Schwartz

Work

Analyst Joseph Schwartz works at LEERINK and is focused on the Healthcare sector with 592 price targets and ratings documented since 2008 spanning on 37 stocks. Analyst's average stock valuation to be materialised ratio is 52.93% with an average time for price targets to be met of 253.86 days.

Most recent stock forecast was given on BMRN, BioMarin Pharmaceutical Inc at 03-Feb-2023.

Joseph Schwartz best performing recommendations are on RETA (REATA PHARMACEUTICALS, INC).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS, INC) at 10/14/2019. The price target of $180 was fulfilled within 4 days with a profit of $79.41 (78.94%) receiving and performance score of 197.36.

Average potential price target upside

AMAG ARNA ASND AUPH BMRN CCXI FOLD ICPT MDCO PTGX QURE RARE SLDB SPRB SRPT AMTI BIIB CBAY ACHN EWTX GOSS IFRX IMRA INSM ONCE RETA RPHM BOLD DSGN PHVS RNA TVTX UTHR ZFGN KALV REGN SYBX

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

14

2 years 4 months 1 days ago

12/17 (70.59%)

$0.4 (2.24%)

60

Hold

10

$-3.75 (-27.27%)

7

2 years 5 months 18 days ago

7/11 (63.64%)

$5.63 (20.89%)

138

Hold

10

$-3.75 (-27.27%)

14

2 years 5 months 19 days ago

1/4 (25%)

$5.83 (60.02%)

6

Hold

10

$-3.75 (-27.27%)

2 years 5 months 30 days ago

3/5 (60%)

$10.1 (29.35%)

211

Hold

13

$-0.75 (-5.45%)

19

3 years 8 months 30 days ago

4/5 (80%)

$4.63 (17.01%)

198

Show more analysts
AMAG ARNA ASND AUPH BMRN CCXI FOLD ICPT MDCO PTGX QURE RARE SLDB SPRB SRPT AMTI BIIB CBAY ACHN EWTX GOSS IFRX IMRA INSM ONCE RETA RPHM BOLD DSGN PHVS RNA TVTX UTHR ZFGN KALV REGN SYBX